SCHEMBL26315829

SCHEMBL26315829

O=C(CCCC(=O)Oc1c(F)c(F)c(F)c(F)c1F)NCCCCCC(=O)OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.50
LMNA P02545 1/20 0.46
TSHR P16473 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
HPGD P15428 2/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C19 P33261 1/20 0.44
HDAC3 O15379 2/20 0.44
HDAC1 Q13547 2/20 0.44
HDAC2 Q92769 2/20 0.44
HDAC10 Q969S8 2/20 0.44
HDAC11 Q96DB2 2/20 0.44
HDAC8 Q9BY41 2/20 0.44
HDAC6 Q9UBN7 2/20 0.44
NCOR2 Q9Y618 2/20 0.44
HDAC4 P56524 1/20 0.44
HDAC7 Q8WUI4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20577215 0.89 LMNA (0.47) EPHX2LMNAMEN1KMT2AHPGD
SCHEMBL26315892 0.88 ALDH1A1 (0.49) EPHX2LMNAMEN1KMT2AHPGD
SCHEMBL2423126 0.87 HTT (0.59) EPHX2LMNASIRT2HTT
SCHEMBL27438957 0.87 LMNA (0.47) EPHX2LMNATSHRMEN1KMT2A
SCHEMBL27438917 0.87 LMNA (0.47) EPHX2LMNATSHRMEN1KMT2A
SCHEMBL17767806 0.87 EPHX2 (0.61) EPHX2LMNATSHRMEN1KMT2A
SCHEMBL20673370 0.87 ALDH1A1 (0.50) EPHX2LMNATSHRMEN1KMT2A
SCHEMBL17767811 0.87 EPHX2 (0.61) EPHX2LMNATSHRMEN1KMT2A
SCHEMBL16217874 0.87 ALDH1A1 (0.50) EPHX2LMNATSHRMEN1KMT2A
SCHEMBL24414987 0.85 HPGD (0.61) EPHX2LMNATSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230293701-A1 LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF ARGORNA PHARMACEUTICALS CO., LTD. (CN) 2023-09-21 US disclosed
US-20230293701-A1 LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF ARGORNA PHARMACEUTICALS CO., LTD. (CN) 2023-09-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230293701-A1 LIGAND COMPOUNDS, CONJUGATES, AND APPLICATIONS THEREOF ASGR1, HAVCR2, SLC10A1 EPHX2 1277/4885LMNA 3071/4885TSHR 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.